sist of four groups: serralysins, matrixins (matrix metalloproteinases), astacins and adamalysins (see 4) .
Matrix metalloproteinases
The matrix metalloproteinases (MMP) gene family presently consists of 21 human members. Matrix metalloproteinases are products of different genes dispersed to the genome, although there is an MMP gene cluster in choromosome 11. Matrix metalloproteinases differ structurally, in that each MMP has the ability to degrade a particular subset of matrix proteins. The protein products are, however, classified by shared functional and structural characteristics (Fig. 1 ). Matrix metalloproteinases 
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can be divided into the following subgroups: (1) collagenases, (2) gelatinases, (3) stromelysins, and stromelysin-like MMPs, (4) matrilysins, membrane-type (MT) MMPs, and (6) other MMPs (Table 1 , see 3, 5) . Together they can degrade all known protein components of the ECM. It is important to remember that most of the MMP substrates defined to date have been demonstrated in vitro but rarely in vivo.
The N-terminal signal peptide directs the protein for secretion into the endoplasmic reticulum and, eventually, out of the cell. All MMPs have a prodomain containing a highly conserved sequence, which has cysteine residue binding the catalytic zinc ion in a catalytic domain, thus keeping the pro-MMP in latent form. The catalytic domain contains the protein-degrading ability of the proteinase. Matrix metalloproteinases are classified on the basis of additional protein domains that contribute to their individual characteristics. A proline-rich hinge region connects the catalytic domain to the following hemopexin domain, which is assumed to mediate additional proteinprotein interactions with substrates and with naturally occurring inhibitors. Fibronectin type II inserts in the catalytic domain of gelatinases modulate protein interactions important in substrate recognition. The transmembrane domain in the Cterminus localizes some cell-surface-bound MMPs to the cell membrane, and short sequence (furin site) between the prodomain and the catalytic domain provides an alternative cleavage site for MMP activation (see 3) . These different combinations of protein motifs within the MMP family, together with individual gene sequences, generate the wide variety of characteristics that are within.
Collagenases
Collagenases-1, -2 and -3 are the major secreted proteinases capable of initiating degradation of native fibrillar collagens (type I, II, III, V and IX) and obviously play a crucial role in degradation of collagenous ECM in various situations. The fibrillar collagens are cleaved at a specific site to produce triple helical fragments, which denaturate spontaneously to gelatin at 37aeC. These fragments can be further degraded by other MMPs (see 5) . Matrix metalloproteinase-1, the first MMP determined by cDNA cloning (6) , cleaves preferentially type III collagen while MMP-8 cleaves type I and II collagens (7, 8) . In vitro MMP-1 is expressed in various normal cells, such as keratinocytes, fibroblasts, endothelial cells, monocytes, macrophages, and chondrocytes (see 5) . It can be detected in vivo in many physiological situations, including embryonic development and wound healing, but also in chronic cutaneous ulcers and many cancers (2, 9) . Matrix metalloproteinase-8 is synthesized by maturing leukocytes in bone marrow, stored intracellularly in granules and released in response to extracellular stimuli (10) . In addition, it has been detected, for example, in human chondrocytes, and synovial fibroblasts (11, 12) . Matrix metalloproteinase-13 was originally cloned from a breast tumor cDNA library (13) and degrades an exceptionally wide spectrum of substrates. Matrix metalloproteinase-13 cleaves preferentially type II collagen and also gelatin more effectively than
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other collagenases (14) . It is expressed during bone development and gingival wound repair (15, 16) as well as in pathological situations, such as in squamous cell carcinomas (SCCs) of different organs, chondrosarcomas and melanoma (see 17) .
Gelatinases
Gelatinase A (MMP-2, 72 kDa gelatinase) is expressed in a variety of normal and transformed cells, including fibroblasts, keratinocytes, endothelial cells and chondrocytes. Gelatinase B (MMP-9, 92 kDa gelatinase) is produced by keratinocytes, monocytes, macrophages, and many malignant cells. Gelatinases are able to degrade type IV, V, VII, X, XI, and XIV collagens, gelatin, elastin, proteoglycan and fibronectin among others (5) and they are believed to have a particularly important role in cancer invasion. Gelatinases demonstrate specific cell-MMP interactions: MMP-2 binds to integrin avb3 and MMP-9 to CD44 (18) . Furthermore, MMP-2 knock-out mice exhibit reduced angiogenesis, impaired tumor growth and decreased metastasis (19) . In MMP-9-deficient mice, endochondral ossification is impaired, resulting in abnormal skeletal growth (20) .
Stromelysins and stromelysin-like MMPs
Stromelysins-1 and -2 (MMPs-3, -10) are highly homologous in primary structure and substrate specificity. Matrix metalloproteinase-3 is expressed by a variety of cells, e.g. keratinocytes, fibroblasts and chondrocytes. It alters the cellular microenvironment and can act as a natural tumor promoter and influence mammary tumor initiation (21) . It is able to activate TGF-b, HB-EGF, IGFBP-3, TNF-a and IL-1b (22) . Matrix metalloproteinase-10 was initially identified in an adenocarcinoma cDNA library (23) . It was later isolated also from a rheumatoid synovial cell cDNA library and shown to be differentially expressed from MMP-3 in human fibroblasts (24) . Matrix metalloproteinase-10 has been detected in tumor cells at least in SCCs of the head, neck and lung (25, 26) . Furthermore, MMP-10 is expressed by migrating keratinocytes in skin wounds (27) and by migrating enterocytes in intestinal ulcers (28) . Stromelysin-3 (MMP-11) was cloned from breast cancer tissue (29) . It is expressed in mesenchymal cells located close to epithelial cells during physiological and pathological tissue remodeling. It has a furin site in its prodomain and thus is processed intracellularly before being released as a mature enzyme (30) . It is expressed in most invasive human carcinomas and is associated with a poor clinical outcome, e.g. in breast cancer (see 31). Mice lacking MMP-11 show reduced tumorigenesis in response to chemical mutagenesis (32) . Matrix metalloproteinase-11 does not seem to cleave matrix components but may increase tumorigenesis by decreasing cancer cell death (33). Human macrophage metalloelastase (MMP-12) was initially found in alveolar macrophages of cigarette smokers (34) . It is the most effective MMP against elastin but has a broad selection of other substrates. The expression of MMP-12 in vivo has been demonstrated mainly in macrophages, such as intestinal ulcerations (28) . Furthermore, it de-grades elastic fibers in atherosclerosis (35) , and aneurysms (36) . Matrix metalloproteinase-12-deficient mice have impaired macrophage-mediated proteolysis and tissue invasion (37) . Interestingly, granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates tumor-infiltrating macrophages to produce metalloelastase, which cleaves plasminogen into angiostatin (38, 39) . Thus, MMP-12 may prevent tumor growth by inhibiting angiogenesis.
Matrilysins
Matrilysin (MMP-7) and endometase are the smallest MMPs, lacking the hinge region and hemopexin domain. Matrix metalloproteinase-7 was originally identified as the small putative uterine metalloproteinase (PUMP) (23) . Unlike most other MMPs expressed or released only in response to injury or disease, MMP-7 is expressed by non-injured, non-inflamed exocrine and mucosal epithelium in many tissues (40) . In addition, MMP-7 is markedly up-regulated in the epithelium of injured airways (41) and the intestine (42), suggesting a key role in the repair of epithelium other than that of skin. Repair of the injured trachea is, indeed, markedly impaired in MMP-7-deficient mice (41) . Matrix metalloproteinase-7 has been suggested to play a role in early stages of tumorigenesis (see 43) . It is up-regulated in many tumors, especially of epithelial origin, such as those of the breast (29) , lung and upper respiratory tract (25) and skin (44) . In addition, intestinal tumorigenesis is reduced in MMP-7-deficient mice (45) . Heparan sulfate proteoglycans bind matrilysin (18) and it is able to release soluble Fas ligand from the cell surface (46) . Interestingly, MMP-7 can also inhibit tumor angiogenesis by generating angiostatin (47) , which has also been shown in vivo (48) . Matrilysin-26 was cloned from fetal (49), placenta (50) , and human endometrial tumor (51) cDNAs. Matrix metalloproteinase-26 has an unusual cysteine-switch propeptide sequence and also a threonine residue adjacent to the Zn-binding site that has been defined as a specific feature of matrilysin. Matrix metalloproteinase-26 is detected in placenta and uterus and is also widely expressed in diverse tumor cell lines and in malignant tumors by RT-PCR (52).
Membrane-type MMPs
The first membrane-type MMP (MT1-MMP) was detected on the surface of invasive tumor cells in 1994 (53) Their domain structure is similar to other MMPs, except for a transmembrane domain and a cytoplasmic tail at the C-terminus. They also contain a furin site between the propeptide and catalytic domain ( Fig. 1) , cleaving of which leads to their activation (59) . Membrane-type 4-and MT6-MMP have a glycosylphosphatidylinositol (GPI)-anchor binding them to the cell surface (60, 61) . Localization of MT-MMPs at the cell surface implies that they might have a significant role in regulation of cell-matrix interactions and activation of other MMPs. Indeed, MT-MMPs activate pro-MMP-2 (62-65), and MT1-and MT2-MMP also MMP-13 (66) . The expression of MT-MMPs, especially MT1-MMP, has been detected in tumor cells or adjacent stromal cells in a variety of human cancers (56, 57, 65, 66, 67) . Membrane type-MMP deficient mice are one of the few MMP knock-outs that have a phenotype, as they have impaired bone development and angiogenesis (68, 69) .
Other MMPs
Matrix metalloproteinase-19 was cloned from mammary gland (70) and liver (71) and isolated also as an autoantigen from the inflamed rheumatoid synovium as RASI (72) . It has a domain structure typical to MMPs, except that it also contains a sequence of 36 residues in C-terminus lacking homology to any other MMP. Matrix metalloproteinase-19 is widely expressed in tissues, including placenta, lung, pancreas, ovary, spleen and intestine (71) . Matrix metalloproteinase-19 is capable of degrading many components of the ECM and BM, but cannot activate any pro-MMPs (73) . The loss of MMP-19 may be a marker of the invasive phenotype, since a progressive loss of MMP-19 expression from in situ carcinoma to invasive breast cancer has been reported (74) . Enamelysin (MMP-20) is exclusively expressed in ameloblasts and odontoblasts of developing teeth (75) and degrades amelogenin, and thus apparently plays a crucial role in tooth enamel formation. Matrix metalloproteinase-23, cloned from an ovary cDNA library (76) , is expressed mainly in the ovary, testis and prostate and might have a specialized role in reproductive processes. It has a unique structure with a short prodomain and also shortened C-terminal domain showing no similarity to hemopexin. It lacks a classic cysteine switch, but it possesses two novel motifs: a cysteine array (CA) and a novel Ig-fold ( Fig. 1) . It might establish a third subclass of membrane-bound MMPs and, thus, a new subclass of the MMP superfamily (77) . Epilysin (MMP-28) was cloned from testis and keratinocyte cDNA libraries (78) . It has a furin activation site and its splicing pattern differs from that of other MMP genes. By Northern analysis, it is expressed at high levels particularly in testis, but also in other tissues. It is also detected by immunohistochemistry in injured epidermis. According to Marchenko et al. (51), lung is the main organ expressing MMP-28, and it is also expressed in a broad range of carcinomas by RT-PCR (79) .
Regulation of MMPs
Matrix metalloproteinases are highly regulated with regard to both secretion and activity. In normal tissue, MMPs are expressed at very low levels, if at all, but their production and activation is rapidly induced when active tissue remodeling is needed (see 3). Matrix metalloproteinase proteins are secreted by the constitutive secretory pathway, except in the case of macrophages and neutrophils, in which MMP-8 and -9 can be stored and released. In addition, MMP-7 is constitutively expressed in the ductal epithelium of exocrine glands (40) . Regulation occurs at multiple levels, including transcription, modulation of mRNA half-life, secretion, compartmentalization, zymogen activation and inhibition of proteolytic activity. Matrix metalloproteinases have natural inhibitors, tissue inhibitors of metalloproteinases (TIMPs), and certain non-specific proteinase inhibitors, such as a2-macroglobulin. In addition, serine protease inhibitors, e.g. a1-antitrypsin and plasminogen activator inhibitors-1 and -2, control general proteolytic activity, including MMPs.
Transcriptional regulation
At the transcriptional level, a variety of cytokines and growth factors (e.g. TNF-a, EGF, bFGF, IL-1, PDGF, IL-6 and TGF-b) induce production of MMPs, depending on the situation and cell type. Also oncogenes, hormones and various chemical agents (e.g. phorbol esters) as well as cell-cell and cell-matrix interactions can induce or repress the expression of MMPs (see 3). Regulatory elements of MMP promoters are remarkably conserved (see 80) . Extracellular stimuli regulate MMP activity through the activator protein (AP)-1 binding site, which is situated in the proximal promoter near the transcription initiation site in inducible MMP genes (MMPs-1, -3, -7, -9, -10, -12, -13 and -19). Activator protein-1 site binds dimeric transcription factors of the Jun and Fos families. The expression of the transcription factors are activated by extracellular signals through three distinct mitogen-activated protein kinase (MAPK) pathways, i.e. extracellular signal-regulated kinase (ERK1, 2), stress-activated protein kinase/Jun N-terminal kinases (SAPK/JNK), and p38. In general, ERK1, 2 cascade is activated by mitogenic signals, while SAPK/JNKs and p38 are activated by cytokines and cellular stress, such as UV light (81) . Matrix metalloproteinase-2, -11, -28 and MT1-MMP genes do not have an AP-1 site in their promoters, but contain putative regulatory elements (82, 83) .
Transcriptional activity usually depends on the AP-1 site interacting with several other cis-acting sequences located throughout the promoter. Multiple polyomavirus enhancer A-binding protein-3 (PEA-3) sites are present in all promoters except MMP-2 and bind members of the ETS family of transcription factors (84) . Individual AP-1 and PEA3 sites often play distinct roles in basal and induced transcription. ETS and AP-1 factors can synergistically activate MMP transcription, and other transcription factors often contribute, particularly in response to growth factors and cytokines. Besides MMP expression, collaboration between ETS and AP-1 has been shown to regulate the promoters of many genes involved in tumor progression (85) .
Proenzyme activation
In most cases the activity of MMPs is controlled extracellularly: they are secreted in an inactive, latent form (pro-MMP). MT-MMPs, MMP-11, -23 and -28 are activated intracellularly by Golgi-associated furin-like proteases. Matrix metalloproteinase-23 is both activated and released from the cell surface by a single cleavage (77) . The latency of MMPs is dependent on cysteine switch. The highly conserved cysteine residue in the prodomain binds covalently to the zinc-ion in the catalytic domain. Disruption of the Cys-zinc bond and cleavage of the prodomain leads to a conformational change and activation of pro-MMPs (3, 86) . Various compounds, e.g. organomercurials (APMA), SH-reactive agents, reactive oxygen and detergents can react with this cystein and convert it to a non-binding form (3). Matrix metalloproteinases can also activate other MMPs (see Table 1 ). Secreted proMMPs can be activated in vitro also with plasmin, trypsin, kallikrein, chymase, and mast cell tryptase. The uPa/plasmin system, as well as other proteinases, activate pro-MMPs, including MMP-2, -9, and -12, in many physiological situations (87) . These activation cascades between MMPs and other proteinases form complex networks in regulating tissue proteolysis.
Tissue inhibitors of MMPs
Matrix metalloproteinases activity is further modulated through interactions with their natural inhibitors: TIMPs-1, -2, -3, and -4 (88, 89) . In gen-eral, TIMPs can inhibit the activity of all MMPs in vitro, except MT1-and MT3-MMPs, which are not inhibited by TIMP-1 (62, 90) . However, various TIMPs have preferential inhibitory capabilities against different pro-MMPs. For instance, TIMP-1 preferentially forms a complex with pro-MMP-9, while TIMP-2 and -4 reduces pro-MMP-2 activation by MT1-MMP (see 89) . The tertiary structure of TIMPs is very similar, as the N-terminus is necessary for MMP inhibition (91, 92) while the Cterminal end affects their specificity (93) . The mechanism involves forming non-covalent stoichiometric complexes with the zinc-binding site of the active form of MMPs (94) .
Except for TIMP-3, which is bound to ECM (95) , TIMPs are present in a soluble form in most tissues and body fluids but show differences in tissue distribution (89) . The expression of TIMP-1 and -3 is up-regulated by various growth factors, cytokines, retinoids, and glucocorticoids, while the expression of TIMP-2 is mainly constitutive. Tissue inhibitors of metalloproteinases play an important role in many biological processes, including fetal development, arthritis, angiogenesis and cancer. An imbalance between TIMP and MMP activities is considered to result in excessive degradation of matrix components in tumor invasion, but the balance between various TIMPs may also be a critical factor in determining the degradative potential of cells in normal and pathological conditions. Besides antitumor activity, TIMPs also have growth promoting activity in an MMP-independent fashion (see 96) . Other functions of TIMPs include matrix binding, inhibition of angiogenesis and induction of apoptosis (97) .
Proteolysis in cancer
Tumorigenesis is a complex, multistage process, where a normal cell undergoes genetic changes resulting in the ability to invade, and spread to, distant sites of the body. Interactions between the tumor and its microenvironment result in the production of proteolytic enzymes crucial for this process. In order for metastasis to occur, a cell must be able to detach from the primary tumor, and invade through BM and interstitial ECM. It must survive the circulation to arrest at the distant capillary bed. In order for the tumor to establish itself in a distant place, the tumor cell must leave the circulation and invade through the matrix again. Furthermore, it has to respond to growth factors, proliferate as a secondary colony, induce angiogenesis and evade host defences (see 22, 98) .
In the adult organism, angiogenesis, i.e. forming of new blood vessels from existing ones, is normally limited to events of tissue repair/remodeling.
In order to maintain continuous growth, malignant tumors depend critically on neovascularization, which enables nutrient and oxygen supply. The ability of the tumor to promote angiogenesis is thought to be one of the early events in the transition of a tumor from the preneoplastic stage to neoplastic phenotype. Studies of various human cancers have also shown a correlation between an increased number of tumor blood vessels and poor prognosis (see 99). The switch into angiogenic phenotype depends on a net balance between positive stimulators (e.g. angiogenin, VEGF or bFGF) and negative regulators (e.g. thrombospondin-1, angiostatin, endostatin) of blood vessel growth. Obviously the understanding of the cellular events and molecular regulation of angiogenesis has huge clinical implications (see 100).
In a developing tumor, there is constant communication between the tumor cells and the surrounding stroma, including matrix components, fibroblasts, endothelial and inflammatory cells (see 101) . Fibroblasts participate in the degradation of ECM by secreting proteases and their activators. Alterations in the tumor stroma involve also the synthesis ECM, as well as changes in cell behavior, adhesion and migration. Some reactions in tumor stroma can be viewed as a non-specific host response in order to slow down tumor progression. Under normal physiological conditions, inflammation is a protective reaction elicited by the host, which serves to eliminate pathogens and initiate repair. Many malignancies may also arise from the areas of inflammation as part of the normal host response, and as such 'tumors may be viewed as wounds that do not heal' (102) . The inflammatory component of a developing neoplasm includes macrophages, neutrophils and mast cells, which are variably loaded with different cytokines, growth factors, cytotoxic mediators, potent angiogenic factors or inhibitors including proteinases, TNF-a, ILs and IFNs, which all can influence the developing tumor (see [103] [104] [105] .
MMPs in tumor progression
The initial observation of the importance of MMPs in cancer biology was that the ability of tumor cells to invade the surrounding tissue correlated with increased MMP levels (106) . Subsequently, many MMP family members have been isolated from tumor cell lines or found to be overexpressed in various tumor tissues. The early hypothesis was that tumors expressed MMPs to make holes in the ECM, thereby initiating the development of metastasis. Although MMPs are typically present at the invasive front, MMP levels can, however, be elevated already in the early 115 stages of tumor progression. Recent work extends the role of MMPs to multiple stages of tumor progression, including growth, cell migration and angiogenesis (see 22) .
Matrix metalloproteinases enable tumor angiogenesis as they allow endothelial cells to invade through BMs to form new blood vessels. They also regulate endothelial cell attachment, proliferation, migration and growth, either directly or by the release of growth factors (see 107) . The importance of MMPs in angiogenesis is substantiated by the fact that synthetic and endogenous MMP inhibitors also reduce angiogenic responses (see 108). Furthermore, MMP-deficient mice (MMP-2, -9 and -14) demonstrate defective angiogenesis (19, 20) . Endothelial cells can produce at least MMP-1, -2, -9, -19 and MT1-MMP, but then again, inflammatory cells and fibroblasts express many MMPs and also contribute to angiogenic phenotype. For instance, infiltration by mast cells and activation of MMP-9 coincides with the 'angiogenic switch' in premalignant lesions during squamous epithelial carcinogenesis (109) . Matrix metalloproteinase-9 promotes tumor angiogenesis in other mouse tumor models as well (110, 111) .
Additional evidence for the critical role of MMPs in tumorigenesis has been provided with transgenic and knock-out mice. For instance, mice lacking MMP-7 and MMP-2 show reduced tumor progression (19, 45) . In addition, chemical mutagenesis results in decreased tumorigenesis in MMP-11-deficient mice (32) . Mice lacking MMP-9 show reduced keratinocyte hyperproliferation and a decreased incidence of invasive tumors during skin carcinogenesis (112) . Furthermore, overexpression of MMP-3 and MMP-7 in transgenic mice led to enhanced tumorigenesis in a breast cancer model (21, 113) . Similarly, overexpression of MMP-1 enhanced tumor formation in a chemically induced skin carcinogenesis model (114) .
Besides the classic role of MMPs in the degradation of ECM in tumorigenesis, new roles are emerging that make the contribution of MMPs much more complex than initially thought. For instance, MMPs cleave receptors involved in cell adhesion, unmask cryptic sites of interaction, activate growth factors, and act on ECM components or other proteins to uncover hidden biologic activities that can affect cell proliferation, migration and angiogenesis. Matrix metalloproteinases are thereby involved in creating an environment suitable for tumor progression (see 4, 9, 115) . Furthermore, MMP-mediated degradation of ECM components may generate inhibitors of angiogenesis and cell growth. Matrix metalloproteinases are now thought to be the most important proteases responsible for generating the potent angiogenesis inhibitor angiostatin, which is a NH 2 -terminal fragment of plasminogen and effectively inhibits endothelial cell proliferation. Matrix metalloproteinases capable of cleaving angiostatin are MMP-3, -7, -9 and -12, of which MMP-12 is the most potent (39, 47) .
MMP expression in tumors
Tumor, stromal and inflammatory cells can all overexpress various MMPs. The stromal expression was originally reported by Basset et al. (29) , who noticed that fibroblasts were responsible for producing MMP-11 in breast cancer. Since then it has been shown by in situ hybridization that stromal expression of MMPs is, in fact, more common than tumor cell expression. For example, MMP-1, -2, -3, -11, and -14 mRNAs are mainly expressed by stromal fibroblasts in the vicinity of tumor cells in many human cancers, including breast, colorectal, lung, prostate and ovarian cancers (see 67) . There are exceptions, such as MMP-7 and -10, which are mainly expressed in tumor cells. Also MMP-13 is usually expressed in tumor cells, and often at the invading front (116) . Tumor cells can induce MMP expression either directly or by secreting soluble factors belonging to the immunoglobulin superfamily, called EMMPRINs, that induce MMP expression in stromal fibroblasts. To date only MMP-1, -2, and -3 have, however, been shown to be induced by EMMPRINs (117, 118) .
The expression patterns (mRNA and proteins) of both MMPs and TIMPs, as well as their combinations, have been studied as prognostic indicators of clinical outcome in many cancers (119) . These studies suggest that MMPs and TIMPs may not only be good targets for cancer therapy but may also have clinical value in identifying subgroups of patients with an increased risk for recurrence. Generally, the expression of high levels of multiple MMP family members correlates positively with tumor aggressiveness, including increased invasive capacity, metastasis and poor patient survival. A direct correlation between MMP expression and the invasive phenotype of human tumors has been detected, for instance, in lung, prostate, stomach, colon, breast, ovary, and oral squamous cell cancers (see 9,67). However, there is no single MMP consistently overexpressed in every tumor type, or a consistent pattern of MMP expression across a variety of human cancers. This reflects the heterogeneity of tumors and differential expression of MMPs during tumor progression. At least MMP-1, -2, -7, -9, -11 and MT1-MMP are frequently overexpressed in many human tumors (see 9,67,107).
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Therapeutic MMP inhibitors
The role of MMPs in many pathological conditions and their low basal expression in normal adult tissues have made them a prominent therapeutic target in cancer and other diseases. Thus, the most efficient approach for cancer therapy would seem to be the inhibition of all MMP activity, as with first generation broad-spectrum MMP inhibitors. Matrix metalloproteinase inhibitors may slow tumor growth by enhancing the development of a fibrotic capsule around the tumor, by inhibiting angiogenesis or by inducing apoptosis in tumor cells. More recently, inhibitors that demonstrate selectivity for a specific MMP subtype have been developed to limit unpleasant side-effects (see 9, 22, 119) . Gene delivery of TIMPs could also result in a beneficial therapeutic effect (120) , but the lack of effective methods has limited the clinical utility of this approach. Synthetic inhibitors interfere with the catalytic machinery in the active site of the MMPs. The hydroxyamate inhibitor batimastat and its analog marimastat were the first inhibitors studied in detail. Non-peptidic MMP inhibitors, such as BAY 12-9566 and AG3340, were synthesized in an attempt to improve the oral bioavailability, pharmaceutical properties and specificity. Also, shark cartilage extract (Neovastat, AE-941, Aeterna), retinoids, tetracycline derivates and bisphosphonates have been used to inhibit MMP activity (see 121). Phase III clinical trials using marimastat, batimastat and BAY 12-9566 alone or in combination with chemotherapy in patients with advanced cancers have been disappointing. This may result from the fact that MMPs are important already in the early stage of tumor progression, and inhibition may not be useful once the tumor has metastasized. Thus, future trials should concentrate on patients with early stage cancers, and the measurements of MMP levels would help identify patients more likely to respond to MMP therapy (122) . Although the development of specific MMP inhibitors may result in more effective compounds, the MMP system is extremely complex, and it is not yet clear which subtypes should be targeted therapeutically to achieve antitumor effects (108) . The dual role of MMPs in angiogenesis also emphasizes the necessity to identify appropriate targets for MMP inhibition.
MMPs in BCC and SCC of skin
Basal cell carcinoma (BCC) is the most common malignancy in humans (Caucasian populations) especially in the elderly population (see 123). The BCC incidence in Europe, USA and Australia increases by 3-6% each year (124) . Basal cell carci-noma is usually slow growing and rarely metastasizes but can cause significant local destruction and disfigurement if treated inadequately. It is considered to arise from multipotential cells within the basal layer of the epidermis or follicular structures and can develop without a premalignant lesion in both a hereditary and sporadic fashion. Disruption of the hedgehog-patched pathway (PTCHgene) is a key event in the development of BCC in both sporadic and hereditary forms (125) . P53 mutations are present in approximately 56% of all types of BCC and are also frequent in SCCs of the head and neck (125, 126) . The PATCHED and p53 genes are major targets of UV radiation and their inactivation leads to uncontrolled cellular proliferation. Basal cell carcinoma typically occurs in areas of chronic sun exposure, which is thought to be the most important and common cause of BCC (127) . Also, ionizing radiation, chemical carcinogens (e.g. arsenic), and possibly infection with human papillomaviruses, have been associated with BCC development. There are several clinical and histologic subtypes of BCC that may exhibit different patterns of behavior and thus more aggressive therapy is often necessary for aggressive BCC variants, such as infiltrating and morpheaform BCCs (see 123) .
Squamous cell carcinoma is a malignant tumor of keratinocytes of the spinous layer of the epidermis. It is the second most common form of skin cancer in Caucasian persons (128) , accounting for 20% of all cutaneous malignancies, and frequently arises on the sun-exposed skin of the middle aged and elderly (129) . Squamous cell carcinoma can occur in many other tissues too, including the mouth, airways, esophagus, uterine cervix and vulva. Evidently, the primary cause of cutaneous SCC is cumulative lifetime sun exposure (especially UVB). Furthermore, ionizing radiation, immune suppression, chronic inflammation, and human papillomavirus (HPV) infection may lead to the development of SCC. There are no generally used reliable prognostic markers for SCC in routine use (130) . The prognostic risk factors include, e.g. diameter, depth of invasion, histologic differentiation, rapid growth, anatomic site, immune suppression, and etiology, so that tumors arising from scars and chronic ulcers tend to be aggressive (129) .
Five to 20% of sun-induced precancerous lesions, known as actinic keratoses, will transform into SCC in 10-25 years (129) . As a result of the fact that some actinic keratoses express MMP-1 (131), its up-regulation has been associated with the early events in SCC development. On the other hand, MMP-1 is up-regulated in migrating keratinocytes in association with wound repair and thus does not serve as an ideal marker for keratinocyte transformation (132) . Overexpression of MMP-2, -3, -10 and -13 has not been observed in actinic keratoses (131, 133, 134 ). Bowen's disease represents cutaneous SCC in situ. Matrix metalloproteinase-9 expression has been reported recently in dyskeratotic foci of Bowen's disease and in the infiltrative edges of microinvasive carcinomas (135) , while Bowen's disease lesions are negative for MMPs-10, -11, -12 and -13 (133) (134) (135) (136) (137) .
Matrix metalloproteinase-1, unlike other collagenases (138), MMP-3 (139), MMP-11 (137), MMP-2 and -9 (140), are mainly expressed by stromal cells surrounding malignant epithelial cells in BCCs. Matrix metalloproteinase-10 mRNA is expressed in BCCs only in epithelial cancer cells with a pattern totally different from its close homologue MMP-3, which is more abundantly expressed in surrounding fibroblasts and only rarely in sclerosing cancer islands (133, 134) . Recently, Cribier et al. (141) reported that MMP-11 was more intensely expressed in aggressive forms of BCC. In aggressive morpheaform (infiltrative) BCCs and recurrent BCCs, MMP-7 was localized at the tumor-stromal interface (44), whereas it was not expressed in other BCC subtypes. Matrix metalloproteinase-13 mRNA was seen in focal areas of keratinized cells and was associated with terminal differentiation of epithelial cells (133) . Macrophages in clinically more aggressive, fibrosing BCCs expressed MMP-12 more often than the keratotic or adenoid BCCs (136) . MT1-MMP expression was found generally in stromal fibroblasts surrounding tumor islands in BCCs (134) . Matrix metalloproteinase-19 or -28 have not been detected in the BCC tumor islands but they are associated with benign hyperproliferation of the epidermis such as that occurring during wound repair (132; Impola and Saarialho-Kere, unpublished observations).
Also, TIMPs have been found in BCCs. According to Varani et al. (138) , MMP inhibitor activity mainly reflected the presence of TIMP-1. Significantly higher levels of TIMP-2 were detected in less infiltrative BCC when compared with SCCs or infiltrative BCCs (142) . Tissue inhibitors of metalloproteinase-3 was present in tumor cells at the tumor edge of infiltrative BCCs (143), while TIMP-1 and -2 were found in stromal cells (142, 144) . In cutaneous and oral SCCs, expression of TIMP-1, -2 and -3 is detected in stromal cells in the vicinity of the tumor (130, 142) , suggesting that their expression represents a host response to limit invasion and angiogenesis.
Squamous cell carcinomas of different organs express several MMP members (see 145) . In SCC of the oral cavity, MMP-3 protein correlated with tumor size, invasion, and high incidence of lymph node metastases (146) . The level of active MMP-2 may serve as a predictive marker of metastasis in oral SCCs (147) . In addition, the high activity of MMP-2 and -9 correlated with the invasiveness of oral SCC (148) and shorter disease-free survival after treatment (149) . According to Sutinen et al. (150) MMP-1 was detected in stromal fibroblasts and also in some neoplastic islands in oral SCCs. Matrix metalloproteinase-2 was expressed in fibroblasts surrounding the carcinoma cells and in the peripheral cell layer in tumor islands. Tissue inhibitor of MMPs-3 was expressed in stromal cells in all oral SCCs, TIMP-1 was detected in some stromal cells, whereas TIMP-2 was not expressed at all. Expression of MMPs and TIMPs was consistently low in oral epithelial dysplasias. In HNSCC, MMP-11 mRNA was detected in stromal cells next to invasive cancer cells and the level of its expression correlated with increased local invasiveness (151) . Matrix metalloproteinase a-9 protein correlated with angiogenic markers and poor survival in HNSCC patients (152) . In esophageal SCCs, MMP-13 protein was detected in tumor cells colocalizing with MT1-MMP, and their expression was related to cancer aggressiveness (153) . Furthermore, elevated protein expression of MMP-7, -9 and MT1-MMP, as well as gelatinase activity, was detected in carcinoma cells correlating with the depth of tumor invasion (154) . The expressions of MMP-1 and MMP-7 were associated with poor prognosis (155, 156) .
Expression of MMP-7, -9, -13 and MT1-MMP have previously been detected in malignantly transformed keratinocytes in SCCs, but not in normal keratinocytes or in premalignant lesions of the skin (44,116,133; Fig. 2 ). Thus, their expression might serve as a marker for the transformation and invasion capacity of cutaneous SCC cells. More precisely, MMP-13 mRNA was expressed by tumor cells at the invading front, but occasionally also by stromal fibroblasts (116) , while its potential activator, MMP-3, was expressed by stromal cells surrounding tumors (133) . Matrix metalloproteinase-7 protein was expressed in SCC cells at the stromal interface surrounding tumor nests (44) , which is also the case for MMP-9 (157). Matrix metalloproteinase-1 mRNA was detected in tumor and stromal cells in SCC of the skin (131), while MMP-11 was typically expressed exclusively in stromal cells (158) . Also, the level of MMP-2 and -9 proteins was up-regulated in SCCs of the skin when compared with BCCs (159) . Indeed MMP-9 expressed by inflammatory cells is functionally involved in distinct processes of epithelial carcinogenesis (112) . Matrix metalloproteinase-28 was not detected in the invasive front of SCCs (132) . The expression of MMP-12 has been shown mainly in macrophages, having a role in macrophage-related proteolysis of elastin in various pathological conditions for example. Interestingly, MMP-12 mRNA and protein are expressed not only by macrophages but also by transformed keratinocytes in cutaneous SCC (136; Fig. 2 ). Furthermore, the level of MMP-12 was higher in histologically more aggressive and poorly differentiated tumor types (grades II and III), suggesting a possible role in the invasion process (136) . In vulvar SCCs, we found it was actually a cancer cellderived MMP-12 that correlated with the aggressiveness and dedifferentiation of the tumors, while macrophage-derived MMP-12 was most abundant in grade I tumors, thus predicting less aggressive behaviour of the tumors (160) . Larger cohorts of patients with HNSCC are needed to predict whether macrophage-derived MMP-12 would serve as a marker of good prognosis.
Matrix metalloproteinase-10 mRNA was expressed in SCCs only in epithelial laminin-5 positive cancer cells while its close homologue MMP-3 was expressed mostly in the stroma. Matrix metalloproteinase-10 expression does not correlate with the invasive behavior of SCCs, but might be induced by the inflammatory matrix remodeling events associated with skin tumors (134) . Membrane type 1-MMP mRNA expression was found both in cancer cells and in stromal fibroblasts surrounding cutaneous SCCs. MT1-MMP-positive cancer cells were detected especially at the invasive edge of tumors (134) . In HNSCC, MT1-MMP protein localized on the cell surface of tumor cells, especially at the invasive areas (161), while its mRNA was detected in stromal cells of the same cancer (162) . Interestingly, a similar discrepancy has been reported for MMP-2 expression in HNSCC and in skin cancer (140) . Thus, it is possible that stromal cells produce MT1-MMP protein, which migrates onto tumor cell surfaces binding fibroblast secreted pro-MMP-2 and activating it as originally reported by Sato et al. (53) . Membrane type 1-MMP can activate latent MMP-13 (66) and, based on previous data (133) , may serve this function at the epithelial front. Interestingly, as MT1-MMP mRNA was produced only by fibroblasts in BCC, it might have a task other than that produced by cancer cells in invasive SCCs. The limited invasion potential of BCC supports this result (134) . Also Ohtani et al. (163) suggested a dual role for MT1-MMP: its expression on the surface of cancer cells might relate to invasive growth, while in fibroblasts it may participate in tissue remodeling processes caused by invasive cancer cells.
Cell migration, keratinocyte hyperproliferation and angiogenesis are essential in both wound healing and tumor invasion. Spatially and temporally controlled expression of several MMPs is essential for normal wound closure. Matrix metalloproteinase-1, -3, -9, and -10 are up-regulated in migrating or proliferating keratinocytes in association with wound repair and thus do not serve as ideal markers for keratinocyte transformation in skin (see 132) . During wound repair, MMP-7, -12, -13, and -14 are not detected in keratinocytes and thus their expression in keratinocyte-derived cells arises cancer suspicion. Interestingly, at least a couple of the newer MMPs, namely MMP-19 and MMP-28, are down-regulated rather than induced in cancers (74, 132) .
Basal cell carcinomas are generally only locally 
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aggressive while SCCs have high metastatic potential. As cell-matrix interactions are important upand down-regulators for MMPs, the changes in the compositions of different BM components, may influence MMP expression. Type VII and IV collagens were less expressed in SCC than BCC (159) . Type IV collagen is the major component of BM and represents the first barrier in tumor cell invasion. Thus, reduced expression of collagen IV, combined with an increased expression of both MMP-2 and MMP-9, could account for the increased invasive potential of SCC vs. BCC (159) . Laminin-5, a protein expressed predominantly in the BM zone, promotes static adhesion in quiescent tissues. However, it also stimulates cell migration and/or invasion after having been cleaved by MMPs such as MMP-2 and MT1-MMP (164, 165) . Laminin-5 production by cancer cells can not be detected in types of BCCs other than the infiltrative areas of sclerosing BCCs (133, 134) . In fact, the simultaneous loss of expression of a6b4 integrin and laminin-5 was detected in BCC cells but not in SCC cells (159, 166, 167) . In HNSCC, laminin5-gamma2 is expressed intracellularly in the peripheral basaloid cells of tumor islands at the invasion front and is not seen in premalignant specimens (168) .
There is growing evidence that integrins can bind or up-regulate MMPs and the integrin profile of BCCs might explain their non-metastasizing behaviour. b1 and b3 integrins were prominently expressed at the periphery of BCC tumor islands, while in SCCs they were absent or variably expressed (169) . Recently, avb6 integrin has been shown to promote invasion of SCC cells through up-regulation of MMP-9 (170). Furthermore, MMP-7 can cleave b4 integrin (171).
Loss or down-regulation of E-cadherin is a key event in the process of tumor invasion and metastasis. Koseki et al. (172) suggested that BCCs do not have much metastatic potential because of the retention of high levels of E-cadherin expression. Matrix metalloproteinases capable of cleaving Ecadherin are MMP-3 and -7 (173), which points out how MMPs may mediate invasion, not only by directly degrading matrix, but also by cleaving transmembrane proteins and receptors. E-cadherin expression is reduced in particularly infiltrative BCCs (174) that are also known to produce MMP-7 (44).
Summary and conclusions
The expression of various MMPs and TIMPs in cutaneous SCC and BCC of the skin in vivo is summarized in Table 2 . Different MMPs might form a network, in which each has a distinct role in the cleavage of a particular matrix component or activation of other MMPs. Stromal cells are the major source of MMPs, but tumor cells, fibroblasts and inflammatory cells all express a distinct set of MMPs capable of complementing the proteolysis needed in tumor progression (see 175) . The expression of MMPs is clearly more abundant in the epithelial compartment of SCCs than BCCs (Table 2) , which might reflect the difference in the invasion capacity of these tumors. Low expression of TIMPs does not necessarily correlate with enhanced invasiveness, as malignant and metastatic tumors often overexpress TIMPs in vivo (46, 176) . However, MMPs are usually expressed more abundantly, as overexpression of TIMPs can block tumor growth (120, 177, 178) . Interestingly, at least MMP-9, -12, and MT1-MMP are all expressed both in tumor and stromal cells in SCCs, so that epithelial expression is more frequent in poorly differentiated tumors when compared with less aggressive SCCs (or BCCs) (134, 136, 159, 160) . In contrast to SCC, TIMP-3 is expressed in cancer cells in BCC and may thus limit MMP activity. On the whole, individual MMPs may have different roles depending on the cell type or state of transformation. For example, MMP-7 and -9 may both induce tumor angiogenesis or inhibit it by generation of angiostatin (48, 109, 179) . Thus, increased expression of MMPs may both confer invasiveness to the tumor cells and, paradoxically, lead to the production of molecules limiting their growth. Similarly, if a particular MMP is expressed by a tumor cell, it may contribute to invasion, while, when expressed by a stromal or inflammatory cell it may have another role, such as regulatory or even protective, in host defense. Expanding knowledge on the role of MMPs in cancer suggests that their functions are much more complex than initially thought. In skin cancer they may not only be good targets for antineoplastic therapy but may turn out to have clinical utility in identifying subgroups of SCC patients at increased risk for recurrence.
